透析患者的肾脏临床药学服务和结果:范围综述

IF 1 Q4 PHARMACOLOGY & PHARMACY
Rebecca Livori BPharm (Hons), GradCertPharmPrac, GradCertHlthSysMgmt, MSc (RenalMedicine), FANZCAP (Neph, MedSafety), MAdPha, Catherine Shaji BPharm (Hons)/MPharm, MAdPha, Dao Gia Nguyen Tran BPharm (Hons)/MPharm, MAdPha, Carla Scuderi BPharm, MClinPharm, PhD, FANZCAP (Neph, Lead&Mgt), FAdPha, Renee Dimond BPharm (Hons), MClinPharm, GradCertEdDes, FANZCAP (Paeds, Edu), MAdPha, Adam Livori BAppSci (NucMed), BPharm (Hons), MClinPharm, FCSANZ, FANZCAP (Cardiol, Res), FAdPha
{"title":"透析患者的肾脏临床药学服务和结果:范围综述","authors":"Rebecca Livori BPharm (Hons), GradCertPharmPrac, GradCertHlthSysMgmt, MSc (RenalMedicine), FANZCAP (Neph, MedSafety), MAdPha,&nbsp;Catherine Shaji BPharm (Hons)/MPharm, MAdPha,&nbsp;Dao Gia Nguyen Tran BPharm (Hons)/MPharm, MAdPha,&nbsp;Carla Scuderi BPharm, MClinPharm, PhD, FANZCAP (Neph, Lead&Mgt), FAdPha,&nbsp;Renee Dimond BPharm (Hons), MClinPharm, GradCertEdDes, FANZCAP (Paeds, Edu), MAdPha,&nbsp;Adam Livori BAppSci (NucMed), BPharm (Hons), MClinPharm, FCSANZ, FANZCAP (Cardiol, Res), FAdPha","doi":"10.1002/jppr.70006","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>People with end-stage kidney disease receiving dialysis in any form commonly experience symptoms associated with their reduced renal function and dialysis treatment, often requiring complex medication therapy to manage. Pharmacists are ideally placed as medicines experts to contribute alongside the multidisciplinary team in optimising patient care. However, specialty dialysis clinical pharmacist roles are beginning to emerge, and few studies have been conducted evaluating the impact of clinical pharmacists in dialysis services.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>This scoping review aimed to identify and evaluate clinical pharmacy services implemented, and outcomes measured, for patients receiving haemodialysis or peritoneal dialysis in the hospital or home setting.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Studies published in English, with participants aged over 18 years receiving any chronic dialysis and involving clinical pharmacist services were included. Studies were excluded if they included only medication supply services or only included patients receiving continuous renal replacement therapy.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Thirty-five studies, published 1997–2024, detailing 17 unique pharmacist interventions for patients receiving dialysis were identified and measured using 17 different outcomes. In the 25 studies, the most common pharmacist interventions included specialist pharmacist medication review (<i>n</i> = 29), pharmacist inclusion in the multidisciplinary team (<i>n</i> = 22), extended pharmacist consultation (<i>n</i> = 20), and targeted adherence counselling (<i>n</i> = 18). The outcomes measured were categorised into three broad themes: therapy-effectiveness, patient-centred, and health-system measures.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The interventions detailed in the included studies highlight an opportunity to extend the scope of pharmacist activities in providing dialysis services in Australia. This expansion would be in line with the ongoing reviews of scope of practice for health professionals and the broader trend of expanding the clinical pharmacist's role. The variability of detail provided in the studies limits transparency and transferability to different dialysis contexts and may impact the achievement of the outcomes described, but further inquiry is warranted.</p>\n </section>\n </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"55 4","pages":"271-286"},"PeriodicalIF":1.0000,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70006","citationCount":"0","resultStr":"{\"title\":\"Renal clinical pharmacy services and outcomes for patients on dialysis: a scoping review\",\"authors\":\"Rebecca Livori BPharm (Hons), GradCertPharmPrac, GradCertHlthSysMgmt, MSc (RenalMedicine), FANZCAP (Neph, MedSafety), MAdPha,&nbsp;Catherine Shaji BPharm (Hons)/MPharm, MAdPha,&nbsp;Dao Gia Nguyen Tran BPharm (Hons)/MPharm, MAdPha,&nbsp;Carla Scuderi BPharm, MClinPharm, PhD, FANZCAP (Neph, Lead&Mgt), FAdPha,&nbsp;Renee Dimond BPharm (Hons), MClinPharm, GradCertEdDes, FANZCAP (Paeds, Edu), MAdPha,&nbsp;Adam Livori BAppSci (NucMed), BPharm (Hons), MClinPharm, FCSANZ, FANZCAP (Cardiol, Res), FAdPha\",\"doi\":\"10.1002/jppr.70006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>People with end-stage kidney disease receiving dialysis in any form commonly experience symptoms associated with their reduced renal function and dialysis treatment, often requiring complex medication therapy to manage. Pharmacists are ideally placed as medicines experts to contribute alongside the multidisciplinary team in optimising patient care. However, specialty dialysis clinical pharmacist roles are beginning to emerge, and few studies have been conducted evaluating the impact of clinical pharmacists in dialysis services.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>This scoping review aimed to identify and evaluate clinical pharmacy services implemented, and outcomes measured, for patients receiving haemodialysis or peritoneal dialysis in the hospital or home setting.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Design</h3>\\n \\n <p>This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Studies published in English, with participants aged over 18 years receiving any chronic dialysis and involving clinical pharmacist services were included. Studies were excluded if they included only medication supply services or only included patients receiving continuous renal replacement therapy.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Thirty-five studies, published 1997–2024, detailing 17 unique pharmacist interventions for patients receiving dialysis were identified and measured using 17 different outcomes. In the 25 studies, the most common pharmacist interventions included specialist pharmacist medication review (<i>n</i> = 29), pharmacist inclusion in the multidisciplinary team (<i>n</i> = 22), extended pharmacist consultation (<i>n</i> = 20), and targeted adherence counselling (<i>n</i> = 18). The outcomes measured were categorised into three broad themes: therapy-effectiveness, patient-centred, and health-system measures.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The interventions detailed in the included studies highlight an opportunity to extend the scope of pharmacist activities in providing dialysis services in Australia. This expansion would be in line with the ongoing reviews of scope of practice for health professionals and the broader trend of expanding the clinical pharmacist's role. The variability of detail provided in the studies limits transparency and transferability to different dialysis contexts and may impact the achievement of the outcomes described, but further inquiry is warranted.</p>\\n </section>\\n </div>\",\"PeriodicalId\":16795,\"journal\":{\"name\":\"Journal of Pharmacy Practice and Research\",\"volume\":\"55 4\",\"pages\":\"271-286\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-05-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.70006\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy Practice and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jppr.70006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Practice and Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jppr.70006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

接受任何形式透析的终末期肾病患者通常会出现与肾功能下降和透析治疗相关的症状,通常需要复杂的药物治疗来控制。理想情况下,药剂师作为药物专家与多学科团队一起为优化患者护理做出贡献。然而,专业透析临床药师角色开始出现,很少有研究评估临床药师在透析服务中的影响。目的:本综述旨在确定和评估在医院或家庭环境中接受血液透析或腹膜透析的患者实施的临床药学服务和测量的结果。设计本范围评价遵循系统评价首选报告项目和范围评价扩展元分析(PRISMA-ScR)指南。研究发表在英文,参与者年龄超过18岁接受任何慢性透析和涉及临床药师服务。如果研究仅包括药物供应服务或仅包括接受持续肾脏替代治疗的患者,则排除研究。结果:1997年至2024年发表的35项研究,详细介绍了17种独特的透析患者药剂师干预措施,并使用17种不同的结果进行了鉴定和测量。在25项研究中,最常见的药剂师干预措施包括专科药剂师用药审查(n = 29)、药剂师纳入多学科团队(n = 22)、扩展药剂师咨询(n = 20)和有针对性的依从性咨询(n = 18)。测量的结果分为三个主题:治疗效果、以患者为中心和卫生系统措施。在纳入的研究中详细的干预措施强调了扩大药剂师在澳大利亚提供透析服务的活动范围的机会。这一扩展将符合正在进行的对卫生专业人员的实践范围的审查,以及扩大临床药师角色的更广泛趋势。研究中提供的细节的可变性限制了透明度和不同透析环境的可转移性,并可能影响所描述结果的实现,但有必要进一步调查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Renal clinical pharmacy services and outcomes for patients on dialysis: a scoping review

Renal clinical pharmacy services and outcomes for patients on dialysis: a scoping review

Background

People with end-stage kidney disease receiving dialysis in any form commonly experience symptoms associated with their reduced renal function and dialysis treatment, often requiring complex medication therapy to manage. Pharmacists are ideally placed as medicines experts to contribute alongside the multidisciplinary team in optimising patient care. However, specialty dialysis clinical pharmacist roles are beginning to emerge, and few studies have been conducted evaluating the impact of clinical pharmacists in dialysis services.

Aim

This scoping review aimed to identify and evaluate clinical pharmacy services implemented, and outcomes measured, for patients receiving haemodialysis or peritoneal dialysis in the hospital or home setting.

Design

This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. Studies published in English, with participants aged over 18 years receiving any chronic dialysis and involving clinical pharmacist services were included. Studies were excluded if they included only medication supply services or only included patients receiving continuous renal replacement therapy.

Results

Thirty-five studies, published 1997–2024, detailing 17 unique pharmacist interventions for patients receiving dialysis were identified and measured using 17 different outcomes. In the 25 studies, the most common pharmacist interventions included specialist pharmacist medication review (n = 29), pharmacist inclusion in the multidisciplinary team (n = 22), extended pharmacist consultation (n = 20), and targeted adherence counselling (n = 18). The outcomes measured were categorised into three broad themes: therapy-effectiveness, patient-centred, and health-system measures.

Conclusion

The interventions detailed in the included studies highlight an opportunity to extend the scope of pharmacist activities in providing dialysis services in Australia. This expansion would be in line with the ongoing reviews of scope of practice for health professionals and the broader trend of expanding the clinical pharmacist's role. The variability of detail provided in the studies limits transparency and transferability to different dialysis contexts and may impact the achievement of the outcomes described, but further inquiry is warranted.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pharmacy Practice and Research
Journal of Pharmacy Practice and Research Health Professions-Pharmacy
CiteScore
1.60
自引率
9.50%
发文量
68
期刊介绍: The purpose of this document is to describe the structure, function and operations of the Journal of Pharmacy Practice and Research, the official journal of the Society of Hospital Pharmacists of Australia (SHPA). It is owned, published by and copyrighted to SHPA. However, the Journal is to some extent unique within SHPA in that it ‘…has complete editorial freedom in terms of content and is not under the direction of the Society or its Council in such matters…’. This statement, originally based on a Role Statement for the Editor-in-Chief 1993, is also based on the definition of ‘editorial independence’ from the World Association of Medical Editors and adopted by the International Committee of Medical Journal Editors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信